logo
  

Catalyst Pharmaceutical Partners (CPRX) Is Rising On Phase 3 Study Results

Catalyst Pharmaceutical Partners (CPRX) announced after the bell Monday that both co-primary endpoints, as well as a secondary endpoint, in its Phase 3 clinical trial of Firdapse demonstrated that Firdapse was significantly superior to placebo. The stock is now up 0.58 after the bell.

Catalyst Pharmaceutical Partners moved in a narrow range throughout Monday's session and closed up by 0.01 at $2.99.

For comments and feedback contact: editorial@rttnews.com

Business News

Get Access to Premium Stock Alerts with RTT Biotech Investor.

Inflation data from the U.S. garnered maximum attention this week on the economics front, along with the interest rate decision by the European Central Bank. Read our stories to find out how these two key events are set to influence monetary policy in the months ahead. Other main news from the U.S. were the release of the minutes of the latest Fed policy session and the jobless claims data. Elsewhere, the interest rate decision by the Bank of Canada was also in focus.

View More Videos
RELATED NEWS
Follow RTT